Votoplam for Huntington's disease: a Phase 3 study
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study tests an investigational drug called Votoplam for people with Huntington's disease. It aims to see if the drug can slow progression of symptoms like movement and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 21 and 70 years old.
- You need a genetic test showing a CAG repeat length of 40 or more.
- Your Huntington's symptoms should be at a moderate stage (not too mild or too advanced).
- You cannot have had gene therapy, cell transplants, or brain surgery for Huntington's.
- You must not have certain heart or liver problems and cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called pridopidine can help slow the progression of Huntington's disease symptoms in adults. Huntington's is a genetic disorder affecting movement, mood, and thinking, and this trial aims to see if pridopidine improves daily functioning and quality of life.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
This early-phase study tests whether VO659 is safe and how the body processes it in people with certain genetic movement disorders (SCA1, SCA3, or Huntington disease). It may help researchers learn the right dose and whether the drug can be given safely.
This Phase 2 study tests whether taking thiamine and biotin together can improve symptoms in people with Huntington’s disease. It looks especially at people with confirmed genetic Huntington’s disease and certain types of movement and/or mood symptoms.
This study is collecting tiny particles called extracellular vesicles from blood and spinal fluid to learn more about Huntington's disease. It aims to find better ways to measure the disease in people who have HD and in those who do not.
This study tests new ways to measure thinking and memory skills in people with Huntington's disease. It aims to find better tools for tracking the disease and could help you understand your cognitive changes.
Hear when a new Huntington Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.